Bessemer Venture Partners Announces a $1.6 Billion Fund to Invest in the Next Generation of Great Companies

February 2015
Authors: Ed Colloton
Today, Bessemer Venture Partners is pleased to announce a new $1.6 billion fund, BVP IX, to invest in innovative companies around the world.
We are now looking for the next generation of BVP-funded companies.

In addition to exploring exciting new areas of opportunity, we continue to focus on sectors in which we've partnered to build category leaders:
Consumer Internet
Enterprise Technology
Cyber Security
Cloud Computing and SaaS
Developer Platforms and Developer Infrastructure
Healthcare IT
Space (our investment in Skybox Imaging—now part of Google—was just the beginning!)

As a firm, BVP invests in companies at all stages. From early investments -Seed/ Series A - in Twilio, Pinterest, Yelp, Skype, and Shopify to growth rounds for LinkedIn and Box, we love to find great teams and support them as they grow. Writing that first check is just the beginning. We continue to support BVP Funded companies through follow-on investments and network relationships, and operational support from experts in business and corporate development, talent acquisition and marketing/communications.

And we make these investments all over the world.

This is an exciting time. In almost every sector of technology, we see disruption as whole categories are reinvented and new categories born. As investors, we are believers in the transformative power of technology. Our mission is to back the world's most talented  entrepreneurs to help them build big businesses and dominate markets.
- See more at:

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.